A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets
Abstract Alzheimer’s disease (AD) is a major and devastating neurodegenerative disease, and the amyloid-β (Aβ) hypothesis is still the central theory for AD pathogenesis. Meanwhile, another major mental illness, depression, is one of the risk factors for AD. From a high-throughput screening (HTS), a...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ced7e5c09b5a420c95dbac43908490dd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ced7e5c09b5a420c95dbac43908490dd |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ced7e5c09b5a420c95dbac43908490dd2021-12-02T15:05:32ZA tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets10.1038/s41598-017-04144-32045-2322https://doaj.org/article/ced7e5c09b5a420c95dbac43908490dd2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04144-3https://doaj.org/toc/2045-2322Abstract Alzheimer’s disease (AD) is a major and devastating neurodegenerative disease, and the amyloid-β (Aβ) hypothesis is still the central theory for AD pathogenesis. Meanwhile, another major mental illness, depression, is one of the risk factors for AD. From a high-throughput screening (HTS), amoxapine, a typical secondary amine tricyclic antidepressant (TCA), was identified to reduce Aβ production. A follow-up investigation on antidepressants showed that most of the TCAs harbour similar activity. Previous studies have indicated that TCAs improve cognitive function in AD mouse models as well as in preliminary clinical data; however, the underlying mechanism is controversial, and the effect on Aβ is elusive. Thus, we developed a secondary screening to determine the molecular target of amoxapine, and serotonin receptor 6 (HTR6) was identified. Knockdown of HTR6 reduced the amoxapine’s effect, while the HTR6 antagonist SB258585 mimicked the activity of amoxapine. Further mechanistic study showed that amoxapine and SB258585 reduced Aβ generation through multiple HTR6-mediated targets, including β-arrestin2 and CDK5. Taken together, our study suggests that amoxapine, though no longer a first-line drug for the treatment of depression, may be beneficial for AD and further structural modification of TCAs may lead to desirable therapeutic agents to treat both AD and depression.Xiaohang LiQinying WangTingting HuYing WangJian ZhaoJing LuGang PeiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Xiaohang Li Qinying Wang Tingting Hu Ying Wang Jian Zhao Jing Lu Gang Pei A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| description |
Abstract Alzheimer’s disease (AD) is a major and devastating neurodegenerative disease, and the amyloid-β (Aβ) hypothesis is still the central theory for AD pathogenesis. Meanwhile, another major mental illness, depression, is one of the risk factors for AD. From a high-throughput screening (HTS), amoxapine, a typical secondary amine tricyclic antidepressant (TCA), was identified to reduce Aβ production. A follow-up investigation on antidepressants showed that most of the TCAs harbour similar activity. Previous studies have indicated that TCAs improve cognitive function in AD mouse models as well as in preliminary clinical data; however, the underlying mechanism is controversial, and the effect on Aβ is elusive. Thus, we developed a secondary screening to determine the molecular target of amoxapine, and serotonin receptor 6 (HTR6) was identified. Knockdown of HTR6 reduced the amoxapine’s effect, while the HTR6 antagonist SB258585 mimicked the activity of amoxapine. Further mechanistic study showed that amoxapine and SB258585 reduced Aβ generation through multiple HTR6-mediated targets, including β-arrestin2 and CDK5. Taken together, our study suggests that amoxapine, though no longer a first-line drug for the treatment of depression, may be beneficial for AD and further structural modification of TCAs may lead to desirable therapeutic agents to treat both AD and depression. |
| format |
article |
| author |
Xiaohang Li Qinying Wang Tingting Hu Ying Wang Jian Zhao Jing Lu Gang Pei |
| author_facet |
Xiaohang Li Qinying Wang Tingting Hu Ying Wang Jian Zhao Jing Lu Gang Pei |
| author_sort |
Xiaohang Li |
| title |
A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| title_short |
A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| title_full |
A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| title_fullStr |
A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| title_full_unstemmed |
A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| title_sort |
tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/ced7e5c09b5a420c95dbac43908490dd |
| work_keys_str_mv |
AT xiaohangli atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT qinyingwang atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT tingtinghu atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT yingwang atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT jianzhao atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT jinglu atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT gangpei atricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT xiaohangli tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT qinyingwang tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT tingtinghu tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT yingwang tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT jianzhao tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT jinglu tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets AT gangpei tricyclicantidepressantamoxapinereducesamyloidbgenerationthroughmultipleserotoninreceptor6mediatedtargets |
| _version_ |
1718388795397636096 |